Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 7/20 | 0.44 |
| ▸ | ESR1 | P03372 | 5/20 | 0.44 |
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | HTR2C | P28335 | 3/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | ACACB | O00763 | 6/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15969100 | 0.85 | ESR2 (0.39) | ESR2ESR1 | |
| SCHEMBL15968947 | 0.83 | ESR2 (0.45) | ESR2ESR1 | |
| SCHEMBL15968710 | 0.79 | ACACB (0.54) | ACACB | |
| SCHEMBL15968295 | 0.79 | ACACB (0.46) | ACACB | |
| SCHEMBL24337629 | 0.74 | ESR1 (0.42) | ESR2ESR1HTR2AHTR2CHTR2B | |
| SCHEMBL11939790 | 0.74 | FEN1 (0.39) | HTR2AHTR2CHTR2B | |
| SCHEMBL11939060 | 0.74 | FEN1 (0.39) | HTR2AHTR2CHTR2B | |
| SCHEMBL11938848 | 0.73 | ALOX5AP (0.36) | — | |
| SCHEMBL11938870 | 0.73 | ALOX5AP (0.36) | — | |
| SCHEMBL21567054 | 0.72 | ACACB (0.36) | HTR2AHTR2CHTR2BACACBPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | ESR2 2876/4885ESR1 2402/4885HTR2A 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.